Clinical Intelligence

Oral BG-12 garners positive phase III results in MS

Wednesday, April 25, 2012 12:15 PM

In a second phase III trial (CONFIRM), Biogen Idec’s oral BG-12 (dimethyl fumarate) demonstrated efficacy across a variety of clinical and radiological outcome measures, as well as favorable safety and tolerability profiles in patients with relapsing-remitting multiple sclerosis (RRMS).

More... »

Europe approves Signifor, first drug for Cushing's disease

Wednesday, April 25, 2012 11:20 AM

The European Commission has approved Novartis’ Signifor (pasireotide) for the treatment of adult patients with Cushing's disease for whom surgery is not an option or for whom surgery has failed. Signifor is the first medicine to be approved in the E.U. targeting Cushing's disease.

More... »

Abbott touts positive results in phase III Parkinson's trial

Wednesday, April 18, 2012 03:39 PM

Abbott has released results from a phase III trial evaluating the company's investigational compound, levodopa-carbidopa intestinal gel (LCIG), for advanced Parkinson's disease.

More... »

Drug reduced number of MS lesions in phase II trial

Wednesday, April 18, 2012 12:37 PM

An investigational oral drug called ONO-4641 reduced the number of lesions in people with multiple sclerosis (MS), according to the results of a phase II clinical trial supported by Ono Pharmaceutical.

More... »

ImmunoGen initiates phase I trial in non-Hodgkin's lymphoma

Wednesday, April 18, 2012 12:14 PM

ImmunoGen, a biotechnology company that develops anticancer therapeutics using Targeted Antibody Payload (TAP) technology, has begun a phase I trial of its IMGN529 anticancer compound.

More... »

Access Pharma reports positive interim results in MuGard phase IV trial

Wednesday, April 18, 2012 11:37 AM

Access Pharmaceuticals, a biopharmaceutical company focused on oncology, has released interim results from its ongoing MuGard phase IV clinical trial in oral mucositis.

More... »

UCB touts positive phase III Cimzia results

Monday, April 16, 2012 03:58 PM

UCB reported positive top-line results from a phase III study designed to evaluate the efficacy and safety of Cimzia (certolizumab pegol) in patients with adult-onset active axial spondyloarthritis (AxSpA), a family of inflammatory rheumatic diseases which includes ankylosing spondylitis (AS).

More... »

FDA clears Cerecor’s FP01

Wednesday, April 11, 2012 04:04 PM

Baltimore-based biopharmaceutical company Cerecor’s Investigational New Drug (IND) application for FP01 for the treatment of cough has cleared the 30 day deliberation period by the FDA. 

More... »

Omeros begins enrollment in second phase III OMS302 trial

Wednesday, April 11, 2012 03:52 PM

Omeros, a Seattle-based biopharmaceutical company, has commenced enrollment in a second phase III clinical trial evaluating OMS302 in intraocular lens replacement (ILR) surgery.

More... »

QRxPharma concludes phase I studies for MoxDuo CR

Wednesday, April 11, 2012 03:28 PM

Australia-based QRxPharma has completed two phase I studies in healthy volunteers for MoxDuo CR, a controlled-release Dual-Opioid utilizing a 3:2 ratio of morphine and oxycodone.

More... »